Advertisement

Digestive Diseases and Sciences

, Volume 49, Issue 1, pp 84–87 | Cite as

IBS Subjects with Methane on Lactulose Breath Test Have Lower Postprandial Serotonin Levels Than Subjects with Hydrogen

  • Mark Pimentel
  • Yuthana Kong
  • Sandy Park
Article

Abstract

We have previously shown that methane on lactulose breath test (LBT) is highly associated with constipation in IBS and that methane gas itself slows small bowel transit in dogs. Previous studies suggest that serotonin may have a role in the control of transit in IBS. In this study, we aim to evaluate the role of serotonin in methane producing IBS subjects. Rome I-positive IBS subjects were recruited into the study after exclusion criteria were met. A fasting LBT was performed after subjects filled out a questionnaire rating the degree of constipation and diarrhea. Within 7 days of this test, subjects returned fasting for determination of serotonin before and after a 75-g oral glucose meal. The serotonin response was compared between hydrogen and methane producing IBS subjects. After 2 subjects were excluded for inadequate blood samples, 18 subjects completed the study. Four of 18 subjects produced methane. The postprandial serotonin level in methane producing IBS subjects was lower than in hydrogen producers (P<0.05). Methane producers had a reduction in serotonin after glucose. Methane producing IBS subjects have reduced postprandial serotonin. Whether methane is a surrogate marker of constipation or contributing to the reduced serotonin remains to be determined.

irritable bowel syndrome lactulose breath test methane serotonin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 45:II43–II47, 1999Google Scholar
  2. 2.
    Bertaccini G: Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastrointestinal tract in the rat. J Physiol (Lond) 153:239–249, 1960Google Scholar
  3. 3.
    Espramer V, Testini A: Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 11:618–623, 1959Google Scholar
  4. 4.
    Kim D-Y, Camilleri M. Serotonin: A mediator of the brain-gut connection. Am J Gastroenterol 95:2698–2709, 2000Google Scholar
  5. 5.
    Inokuchi H, Kawai K, Takeuchi Y, Sano Y: Immunohistochemical demonstration of EC cells in rat gastrointestinal tract. Histochemistry 74:453–456, 1982Google Scholar
  6. 6.
    Bülbring E, Lin RCY: The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 140:381–407, 1958Google Scholar
  7. 7.
    Bülbring E, Crema A: Observations concerning the action of 5-hydroxytryptamine on the peristaltic reflex. Br J Pharmacol 13:444–457, 1958Google Scholar
  8. 8.
    Bülbring E, Crema A: The action of 5-hydroxytryptamine, 5-hydroxytryptophan and reserpine on intestinal peristalsis in anaesthetized guinea pigs. J Physiol 146:29–53, 1959Google Scholar
  9. 9.
    Costa M, Furness JB: The peristaltic reflex: An analysis of the nerve pathways and their pharmacology. Naunyn-Schmeidelberg Arch Pharmacol 294:47–60, 1976Google Scholar
  10. 10.
    Bearcroft CP, Perrett D, Farthing MJG: Postprandial plasma 5-hyroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998;42:42–46, 1998Google Scholar
  11. 11.
    Müller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Alim Pharmacol Ther 15:1655–1666, 2001Google Scholar
  12. 12.
    Camilleri M, Chey WY, Mayer EA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 161:1733–1740, 2001Google Scholar
  13. 13.
    Camilleri M, Northcutt AR, Kong S, et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355:1035–1040, 2000Google Scholar
  14. 14.
    Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503–3506, 2000Google Scholar
  15. 15.
    Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized placebo controlled study. Am J Gastroenterol 98:412–419, 2003Google Scholar
  16. 16.
    Pimentel M, Mayer AG, Park S, et al.: Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 48:86–92, 2003Google Scholar
  17. 17.
    Lin HC, Pimentel M, Chen JH: Intestinal transit is slowed by luminal methane. Neurogastroenterol Motil 4:437, 2002Google Scholar
  18. 18.
    Hede AR, Andersson L, Post C: Effect of homologous series of halogenated methanes on pulmonary uptake of 5-hydroxtryptamine in isolated perfused rat lung. Acta Pharmacol Toxicol 57:291–296, 1985Google Scholar
  19. 19.
    Drossman DA, Richter JE, et al. (eds): Functional gastrointestinal disorders: Diagnosis, pathophysiology and treatment: a multinational consensus. Boston, Little, Brown, 1994Google Scholar
  20. 20.
    O'Hara R, Fox RO, Cole JW: Serotonin release mediated by intraluminal sucrose solutions. Surg Forum 10:215, 1959Google Scholar
  21. 21.
    Drapana T, McDonald JC, Stewart JD: Serotonin release following instillation of hypertonic glucose into the proximal intestine. Ann Surg 156:528–536, 1962Google Scholar
  22. 22.
    Levitt MD: Production and excretion of hydrogen gas in man. N Engl J Med 281:122–127, 1969Google Scholar
  23. 23.
    Levitt MD, French P, Donaldson RM Jr: Use of hydrogen and methane excretion in the study of the intestinal flora. J Lab Clin Med 72:988, 1968 (abstr)Google Scholar
  24. 24.
    Bond JH Jr, Engel RR, Levitt MD: Factors influencing pulmonary methane excretion in man. An indirect method of studying the in situ metabolism of the methane-producing colonic bacteria. J Exp Med 133:572–588, 1971Google Scholar
  25. 25.
    Levitt MD, Ingelfinger FJ: Hydrogen and methane production in man. Ann NY Acad Sci 150:75–81, 1968Google Scholar
  26. 26.
    Levitt MD, Bond JH Jr: Volume, composition and source of intestinal gas. Gastroenterology 59:921–929, 1970Google Scholar
  27. 27.
    Calloway DH, Murphy EL: The use of expired air to measure intestinal gas formation. Ann NY Acad Sci 150:82–95, 1968Google Scholar
  28. 28.
    Bond JH Jr, Engel RR, Levitt MD: Factors influencing pulmonary methane excretion in man. An indirect method of studying the in situ metabolism of the methane-producing colonic bacteria. J Exp Med 133:572–588, 1971Google Scholar
  29. 29.
    Pitt P, DeBruijn KM, Beeching MF, et al.: Studies on breath methane: the effect of ethnic origins and lactulose. Gut 21:951–959, 1980Google Scholar
  30. 30.
    Bjorneklett A, Jenssen E: Relationship between hydrogen (H2) and methane (CH4) production in man. Scand J Gastroenterol 17:985–992, 1982Google Scholar
  31. 31.
    Stadtman TC: Methane fermentation. Annu Rev Microbiol 21:121–142, 1967Google Scholar
  32. 32.
    Fiedorek SC, Pumphrey CL, Casteel HB: Breath methane production in children with constipation and encoparesis. J Pediatr Gastroenterol 10:473–477, 1990Google Scholar
  33. 33.
    Weaver GA, Krause JA, Miller TL, Wollin MJ: Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. Gut 27:698–704, 1986Google Scholar
  34. 34.
    Bertaccini G: Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastrointestinal tract in the rat. J Physiol (Lond) 153:239–249, 1960Google Scholar
  35. 35.
    Espramer V, Testini A: Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 11:618–623, 1959Google Scholar
  36. 36.
    Kim D-Y, Camilleri M. Serotonin: A mediator of the brain-gut connection. Am J Gastroenterol 95:2698–2709, 2000Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • Mark Pimentel
    • 1
    • 2
  • Yuthana Kong
    • 1
    • 2
  • Sandy Park
    • 1
    • 2
  1. 1.The GI Motility Program, Department of MedicineCSMC Burns and Allen Research Institute, Cedars-Sinai Medical CenterLos Angeles
  2. 2.School of MedicineUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations